Background: Streptococcus pyogenes most commonly cause pharyngitis, also has been associated with invasive infection as sepsis & fulminate systemic infections . It is imperative cause for fatal condition in children like acute rheumatic fever & rheumatic heart disease. Development of strains that resistant to antibiotics makes such disease a dangerous clinical challenge particularly in children, so in order to overcomingthis resistance, a nonsteroidal anti-inflammatory drugs (NSAID) is repurposed as antimicrobials against this microorganisms to be combined with the anti-microbial suggested by WHO rule of care.Aims: To evaluate the antimicrobial activity of aspirin & an aspirin-cefixime combination against multidrugresistant S.pyogenes isolated from clinical cases of pharyngitis.Materials, Patients and Methods: S.pyogenes,a multidrug-resistant strain, was isolated from patients had pharyngitis. It was cultivated for determination of MIC for aspirin-cefixime combination in relationship with each drug alone &to determine combination index.Results and Conclusions: a significant synergism was found between aspirin-cefixime ( combination index ˂ 1) P= 0.009& Z score= 2.5 further confirmation of MIC had assessed bytwo folds of dilutions to achieve reasonable evidence.
Conclusion:There was a significant synergistic effect achieved from combining aspirin with cefixime against S.pyogenes isolate in culture .
Recommendations:We recommended further evaluation for the antistreptococcal effect of the combined aspirin-cefixime on more dilutions of MIC assay & to investigate data of this combination clinically in patients with S.pyogenes pharyngitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.